TNFRSF18 and neoplasm: Compared to combination therapy with anti-PD-1 and anti-GITR (murine IgG2a with effector function), the bispecific mAb induces expansion of TAA-specific memory T cells with consequent rejection of tumor in challenge/rechallenge experiments [56].